A Deep Dive Into Aquestive Following The FDA's Approval Of Riluzole

Aquestive Therapeutics Inc (NASDAQ: AQST) made a move this week, gaining about 17% Monday after the FDA approved one of its drugs ahead of a Nov. 30 PDUFA action date.

The thinly traded, micro-cap stock is little changed on a year-to-date basis, although it has traded in the range of $2.95-$8.54.

The company is expected to complete the rolling regulatory submission for another investigational drug before the end of November.